Literature DB >> 27313327

Adjuvant rituximab to prevent TTP relapse.

Adam Cuker1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27313327     DOI： 10.1182/blood-2016-04-710475

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

Review 1.  The remarkable diversity of thrombotic thrombocytopenic purpura: a perspective.

Authors:  James N George
Journal:  Blood Adv       Date:  2018-06-26

2.  [Clinical analysis of 61 patients with thrombotic thrombocytopenic purpura].

Authors:  M J Shi; W B Gao; W F Huang; J H Zhu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-09-30

3.  Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura.

Authors:  Hanny Al-Samkari; Rachael F Grace; Jean M Connors
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

4.  TMA secondary to SLE: rituximab improves overall but not renal survival.

Authors:  Fangfang Sun; Xiaodong Wang; Wanlong Wu; Kaiwen Wang; Zhiwei Chen; Ting Li; Shuang Ye
Journal:  Clin Rheumatol       Date:  2017-08-30       Impact factor: 2.980

5.  Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Amit Gokhale; Jeanne E Hendrickson; Christopher Tormey; Alfred Ian Lee
Journal:  Blood Adv       Date:  2020-02-11

6.  Myocardial Infarction as an Early Presentation in Thrombotic Thrombocytopenic Purpura: A Rare Case Series.

Authors:  Sumit Dahal; Dipesh K C Ghimire; Saroj Sapkota; Suyash Dahal; Paritosh Kafle; Manjul Bhandari
Journal:  J Investig Med High Impact Case Rep       Date:  2018-05-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.